Autopsy report · NCT00908414

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

“strategic decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Tibotec Pharmaceuticals, Ireland

Sponsor type

Industry

Conditions

HIV Infections

Interventions

TMC589337 40 mg; TMC589337 100 mg; TMC589337 200 mg; TMC589337 400 mg; TMC589354 40 mg; TMC589354 100 mg

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (92% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (91% match in meaning)
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (90% match in meaning)
• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (90% match in meaning)
• A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
  “Strategic considerations” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.